Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020

Rhea-AI Summary

Viela Bio (Nasdaq: VIE) announced the acceptance of four abstracts for the 8th Joint Congress of ACTRIMS and ECTRIMS, taking place virtually from September 11-13, 2020. This includes a late-breaker presentation on pharmacodynamic modeling of inebilizumab for neuromyelitis optica spectrum disorders scheduled for September 26, 2020. Presentations will cover critical findings from the N-MOmentum trial, highlighting insights into patient responses and MRI activity in neuromyelitis optica.

Positive

• Four abstracts accepted for prestigious scientific congress highlighting ongoing research.
• Late-breaker presentation may attract attention to inebilizumab's effectiveness.

Negative

• None.

GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8^th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The congress will be held virtually on September 11-13, 2020 with an Encore event featuring late-breaker and COVID-19 presentations on September 26, 2020.

Poster Presentations:
Title: AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (P0189)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Title: Serum neurofilament light chain levels (sNfL) correlate with attack-related disability in neuromyelitis optica (P0155)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Title: Quiescent MRI activity in NMOSD: results from the N-MOmentum randomized placebo-
controlled trial (P0229)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Late-Breaker Presentation:
Title: Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (LB1239)
Date: Saturday, September 26, 2020
Time: 8:00 AM EDT

About Viela Bio

Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.

Source: Viela Bio

Contacts:

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com 

Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com

FAQ

What is the significance of VIE's presentation at the 8th Joint Congress?

The presentations showcase important research findings related to neuromyelitis optica and highlight Viela Bio's commitment to advancing treatments.

When will the late-breaker presentation for VIE take place?

The late-breaker presentation will occur on September 26, 2020, focusing on pharmacodynamic modeling of inebilizumab.

What topics will be covered in the presentations at the congress for VIE?

Topics include AQP4-IgG seronegative patients, serum neurofilament levels, and MRI activity results from the N-MOmentum trial.

How does the congress affect Viela Bio's stock performance?

Presentations at the congress could potentially boost investor confidence in VIE by demonstrating the efficacy of their treatments.